Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

COVID-19-related mortality among hematopoietic stem cell transplantation (HSCT) recipients in the pre-vaccine era ranged between 22 and 33%. The Pfizer/BioNTech BNT162b2 vaccine demonstrated significant immunogenicity and efficacy in the healthy population; however, its long-term effects on allogene...

Descripción completa

Detalles Bibliográficos
Autores principales: Henig, Israel, Isenberg, Jonathan, Yehudai-Ofir, Dana, Leiba, Ronit, Ringelstein-Harlev, Shimrit, Ram, Ron, Avni, Batia, Amit, Odelia, Grisariu, Sigal, Azoulay, Tehila, Slouzkey, Ilana, Zuckerman, Tsila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145595/
https://www.ncbi.nlm.nih.gov/pubmed/37112688
http://dx.doi.org/10.3390/vaccines11040775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145595/
https://www.ncbi.nlm.nih.gov/pubmed/37112688
http://dx.doi.org/10.3390/vaccines11040775

Ejemplares similares